The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

This site is intended only for healthcare professionals of the United States, its territories, and Puerto Rico. Non-US residents click here.

5-Year Data See the results of the longest reported controlled clinical study of male pattern hair loss. View study results.

When to start treatment In the longest reported controlled clinical study of male pattern hair loss patients ever conducted ... Men who started treatment with placebo and were switched to PROPECIA® (finasteride) 1 year later never caught up to the men who were treated with PROPECIA for the full 5 years. Pooled data from 2 vertex studies (mean baseline hair count=876). P<0.001 PROPECIA vs baseline at each time point. P<0.001 placebo vs baseline at each time point. The difference in hair count mean change from baseline of 277 hairs was seen between men taking PROPECIA vs placebo at 5 years. * Changes in hair count were measured within a 1-inch diameter circle at the anterior leading edge of the thinning vertex area.   If PROPECIA has not maintained hair count or regrown visible hair within 12 months, further treatment is unlikely to be of benefit. Withdrawal of treatment leads to reversal of effect within 12 months.   PROPECIA is the first oral therapy indicated for the treatment of male pattern hair loss in MEN ONLY. Safety and efficacy were demonstrated in men, aged 18 to 41, with mild to moderate hair loss of the vertex and anterior mid-scalp area. Efficacy in bitemporal recession has not been established.   PROPECIA is not indicated in women or children.   Clinical Hair Count Results Product Data and Highlights

	PROPECIA is a registered trademark of Merck & Co., Inc. 20550391(1)-05/05-PRP